Evidence map›Paper›PMID 41824583›Full record

ArticleScience advances2026

Microrobotic copper-rich electrochemical interfacing for targeted cancer theranostics in the gut.

Junghwan Byun, Siyeon Jang, Yingdan Wu, Jiwoong Choi, Ugur Bozuyuk, Junghyeon Ko, Alp Can Karacakol, Eun Hye Kim, Sungwoo Chun, Amirreza Aghakhani and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Junghwan ByunElectronic and Hybrid Materials Research Center, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.ORCID 0000-0003-4135-967X
Siyeon JangPhysical Intelligence Department, Max Planck Institute for Intelligent Systems, Stuttgart 70569, Germany.
Yingdan WuState Key Laboratory of Robotics and Systems, Harbin Institute of Technology, Harbin 150001, China.ORCID 0000-0002-4263-2888
Jiwoong ChoiMedicinal Materials Research Center, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.
Ugur BozuyukPhysical Intelligence Department, Max Planck Institute for Intelligent Systems, Stuttgart 70569, Germany.ORCID 0000-0001-9555-2307
Junghyeon KoElectronic and Hybrid Materials Research Center, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.ORCID 0000-0003-1537-1931
Alp Can KaracakolPhysical Intelligence Department, Max Planck Institute for Intelligent Systems, Stuttgart 70569, Germany.ORCID 0000-0003-1241-0800
Eun Hye KimDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea.ORCID 0000-0002-4224-6207
Sungwoo ChunDepartment of Electronics and Information Engineering, Korea University, Sejong 30019, Republic of Korea.ORCID 0000-0002-8533-0388
Amirreza AghakhaniDepartment Institute of Biomaterials and Biomolecular Systems (IBBS), University of Stuttgart, Stuttgart 70569, Germany.ORCID 0000-0002-4301-4053
Seungjun ChungSchool of Electrical Engineering, Korea University, Seoul 02841, Republic of Korea.ORCID 0009-0003-4706-5880
Jiachen ZhangDepartment of Biomedical Engineering, City University of Hong Kong, Hong Kong SAR China.ORCID 0000-0002-6488-6686
Yoosoo YangDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea.ORCID 0000-0003-3279-4362
Metin SittiPhysical Intelligence Department, Max Planck Institute for Intelligent Systems, Stuttgart 70569, Germany.ORCID 0000-0001-8249-3854

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The exquisite spatiotemporal regulation of drug biodistribution is paramount for optimal targeted cancer theranostics. Robotic ingestible devices promise to reinvent the way drugs interact with gastrointestinal (GI) tissues and malignant tumors. However, no study has yet demonstrated theranostic functions beyond merely conveying synthetic drugs. Here, we present an orally administrable, functionally integrated soft microrobot capable of localized therapeutic regulation of copper (Cu)-dependent cell death mechanism, termed "cuproptosis" within GI tumors. By leveraging the interplay of mechanical, electrical, and biochemical functions, the robot actively targets and grasps the tumor and generates anticancer Cu-rich electrochemical interfacing with the targeted tumor microenvironment. This tumor-robot interface, characterized by in situ generated electric multipole fields and on-demand burst Cu

Indexed as

CopperTheranostic NanomedicineAnimalsAntineoplastic AgentsCell Line, TumorHumansMiceSwineTumor MicroenvironmentAntineoplastic AgentsCopper

Identifiers

PMID41824583
PMCPMC12985744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.